|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hainaut P and Plymoth A: Targeting the
hallmarks of cancer: Towards a rational approach to next-generation
cancer therapy. Curr Opin Oncol. 25:50–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mazzaferro V, Regalia E, Doci R, Andreola
S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and
Gennari L: Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med.
334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng SS, Xu X, Wu J, Chen J, Wang WL,
Zhang M, Liang TB and Wu LM: Liver transplantation for
hepatocellular carcinoma: Hangzhou experiences. Transplantation.
85:1726–1732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu J, Zhang D, Luo W, Yu Y, Yu J, Li J,
Zhang X, Zhang B, Chen J, Wu XR, et al: X-linked inhibitor of
apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP
dissociation inhibitor (RhoGDI)-dependent regulation of the
cytoskeleton. J Biol Chem. 286:15630–15640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olofsson B: Rho guanine dissociation
inhibitors: Pivotal molecules in cellular signalling. Cell Signal.
11:545–554. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moissoglu K, McRoberts KS, Meier JA,
Theodorescu D and Schwartz MA: Rho GDP dissociation inhibitor 2
suppresses metastasis via unconventional regulation of RhoGTPases.
Cancer Res. 69:2838–2844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcia-Mata R, Boulter E and Burridge K:
The ‘invisible hand’: Regulation of RHO GTPases by RHOGDIs. Nat Rev
Mol Cell Biol. 12:493–504. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
DerMardirossian C and Bokoch GM: GDIs:
Central regulatory molecules in Rho GTPase activation. Trends Cell
Biol. 15:356–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang KP, Zhang JL, Ren YH and Qian YB:
Talin-1 correlates with reduced invasion and migration in human
hepatocellular carcinoma cells. Asian Pac J Cancer Prev.
15:2655–2661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu W, Wang J and Wen T: Downregulation of
Rho-GDI gamma promotes differentiation of neural stem cells. Mol
Cell Biochem. 311:233–240. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhen H, Yang S, Wu H, Wang S, Lv J, Ma L
and Zhang X: LyGDI is a promising biomarker for ovarian cancer. Int
J Gynecol Cancer. 20:316–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao L, Wang H, Sun X and Ding Y:
Comparative proteomic analysis identifies proteins associated with
the development and progression of colorectal carcinoma. FEBS J.
277:4195–4204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ronneburg H, Span PN, Kantelhardt E,
Dittmer A, Schunke D, Holzhausen HJ, Sweep FC and Dittmer J: Rho
GDP dissociation inhibitor α expression correlates with the outcome
of CMF treatment in invasive ductal breast cancer. Int J Oncol.
36:379–386. 2010.PubMed/NCBI
|
|
15
|
Yamashita T, Okamura T, Nagano K, Imai S,
Abe Y, Nabeshi H, Yoshikawa T, Yoshioka Y, Kamada H, Tsutsumi Y and
Tsunoda S: Rho GDP-dissociation inhibitor alpha is associated with
cancer metastasis in colon and prostate cancer. Pharmazie.
67:253–255. 2012.PubMed/NCBI
|
|
16
|
Li W, Wang H, Jin X and Zhao L: Loss of
RhoGDI is a novel independent prognostic factor in hepatocellular
carcinoma. Int J Clin Exp Pathol. 6:2535–2541. 2013.PubMed/NCBI
|
|
17
|
Wu Y, McRoberts K, Berr SS, Frierson HF
Jr, Conaway M and Theodorescu D: Neuromedin U is regulated by the
metastasis suppressor RhoGDI2 and is a novel promoter of tumor
formation, lung metastasis and cancer cachexia. Oncogene.
26:765–773. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma L, Xu G, Sotnikova A, Szczepanowski M,
Giefing M, Krause K, Krams M, Siebert R, Jin J and Klapper W: Loss
of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor,
in Hodgkin lymphoma. Br J Haematol. 139:217–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moon HG, Jeong SH, Ju YT, Jeong CY, Lee
JS, Lee YJ, Hong SC, Choi SK, Ha WS, Park ST and Jung EJ:
Up-regulation of RhoGDI2 in human breast cancer and its prognostic
implications. Cancer Res Treat. 42:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho HJ, Baek KE, Park SM, Kim IK, Choi YL,
Cho HJ, Nam IK, Hwang EM, Park JY, Han JY, et al: RhoGDI2
expression is associated with tumor growth and malignant
progression of gastric cancer. Clin Cancer Res. 15:2612–2619. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y and Zhang B: D4-GDI, a Rho GTPase
regulator, promotes breast cancer cell invasiveness. Cancer Res.
66:5592–5598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding J, Huang S, Wu S, Zhao Y, Liang L,
Yan M, Ge C, Yao J, Chen T, Wan D, et al: Gain of miR-151 on
chromosome 8q24.3 facilitates tumour cell migration and spreading
through downregulating RhoGDIA. Nat Cell Biol. 12:390–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Wang B, Liao Q, An H, Li W, Jin X,
Cui S and Zhao L: Overexpression of RhoGDI, a novel predictor of
distant metastasis, promotes cell proliferation and migration in
hepatocellular carcinoma. FEBS Lett. 588:503–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li C, Tan YX, Zhou H, Ding SJ, Li SJ, Ma
DJ, Man XB, Hong Y, Zhang L, Li L, et al: Proteomic analysis of
hepatitis B virus-associated hepatocellular carcinoma:
Identification of potential tumor markers. Proteomics. 5:1125–1139.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY,
Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1
overexpression predicts tumor recurrence of hepatocellular
carcinoma after liver transplantation. Med Oncol. 29:1810–1816.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuan SX, Yang F, Yang Y, Tao QF, Zhang J,
Huang G, Yang Y, Wang RY, Yang S, Huo XS, et al: Long noncoding RNA
associated with microvascular invasion in hepatocellular carcinoma
promotes angiogenesis and serves as a predictor for hepatocellular
carcinoma patients' poor recurrence-free survival after
hepatectomy. Hepatology. 56:2231–2241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livraghi T, Makisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fernandez M, Semela D, Bruix J, Colle I,
Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol.
50:604–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosmorduc O and Housset C: Hypoxia: A link
between fibrogenesis, angiogenesis, and carcinogenesis in liver
disease. Semin Liver Dis. 30:258–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi L, Wu LL, Yang JR, Chen XF, Zhang Y,
Chen ZQ, Liu CL, Chi SY, Zheng JY, Huang HX, et al: Serum
peroxiredoxin3 is a useful biomarker for early diagnosis and
assessemnt of prognosis of hepatocellular carcinoma in Chinese
patients. Asian Pac J Cancer Prev. 15:2979–2986. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thomas MB, Jaffe D, Choti MM, Belghiti J,
Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al:
Hepatocellular carcinoma: Consensus recommendations of the national
cancer institute clinical trials planning meeting. J Clin Oncol.
28:3994–4005. 2010. View Article : Google Scholar : PubMed/NCBI
|
